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Mammary MCF-10A cells seeded on reconstituted basement membrane form spherical 
structures with a hollow central lumen termed acini which are a physiologically-relevant 
model of mammary morphogenesis. Bcl-2 associated athanogene 1 (Bag-1) is a 
multifunctional protein overexpressed in breast cancer and ductal carcinoma in situ (DCIS). 
When present in the nucleus Bag-1 is predictive of clinical outcome in breast cancer. Bag-1 
exists as three main isoforms, which are produced by alternative translation initiation from a 
single mRNA. The long isoform of Bag-1, Bag-1L, contains a nuclear localisation sequence 
not present in the other isoforms. When present in the nucleus Bag-1L, but not the other 
Bag-1 isoforms, can interact with and modulate the activities of oestrogen, androgen, and 
vitamin D receptors, Overexpression of Bag-1 mRNA in MCF-10A, is known to produce acini 
with luminal filling reminiscent of DCIS. As this mRNA predominantly overexpresses the 
short isoform of Bag-1, Bag-1S, we set out to examine whether the nuclear Bag-1 isoform is 
sufficient to drive premalignant change by developing a Bag-1L overexpressing MCF-10A 
model. Two clones differentially overexpressing Bag-1L were grown in 2D and 3D cultures 
and compared to an established model of HER2-driven transformation. In 2D cultures, Bag-
1L overexpression reduced proliferation but did not affect insulin responsiveness or 
clonogenicity. Acini formed by Bag-1L-overexpressing cells exhibited reduced luminal 
clearing when compared to controls. An abnormal branching morphology was also observed 
which correlated with the level of Bag-1L overexpression suggesting further malignant 
change. Treatment with Thio-2, a small-molecule inhibitor of Bag-1 reduced the level of 
branching. In summary, 3D cultures of MCF-10A mammary epithelial cells overexpressing 
Bag-1L demonstrate a premalignant phenotype with features of DCIS. Using this model to 
test the small molecule Bag-1 inhibitor, Thio-2, reveals its potential to reverse the atypical 
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Investigation of breast cancer progression has traditionally relied on two-dimensional (2D) in 
vitro cell models to elucidate the molecular drivers associated with this disease. However, 
2D culture has spatial and cell differentiation limitations.10, 21 3D cell models provide an 
important additional experimental tool as they recapitulate several aspects of normal and 
tumour tissue architecture. When seeded in reconstituted basement membrane (BM), 
human mammary epithelial normal cells or non-tumourigenic cell lines, such as MCF-10A, 
follow a highly-regulated morphogenetic program to form organised growth-arrested 3D 
spherical structures with a central lumen termed acini.9, 32 This involves polarisation of BM-
attached outer cells with concomitant anoikis and metabolic changes of luminal cells that are 
no longer in contact with the BM (BM-detached).8, 37 Expression analysis of acini 
morphogenesis has led to the identification of a 3D molecular signature, comprising genes 
that are downregulated during this process, which accurately predicts outcome in breast 
cancer patients.13, 25  
Contrary to normal breast cells, breast tumour cells and breast cancer cell lines continue to 
proliferate and give rise to larger acini with altered external morphology and no central lumen 
due to defects in anoikis and metabolism of BM-detached cells;21, 27, 32, 37 these structures 
bear features of ductal carcinoma in situ (DCIS), a precursor to invasive ductal carcinoma.5 
Comparison of the transcriptional profiles of a panel of human breast cancer cell lines 
correlates with their 3D morphology and enables clustering into four main phenotypic 
subclasses, which are associated with clinically distinct subgroups.21 The majority of basal B 
subtype cell lines form invasive stellate structures, which lack E-cadherin and EGFR/HER2 
expression, while luminal and basal A subtypes form round, mass, or grape-like structures, 
which typically overexpress HER2, a marker of poor prognosis in breast cancer.21, 42 
Consistent with this, HER2 overexpression or activation in MCF-10A cells results in atypical, 
grape-like acinar morphology and impedes lumen formation by attenuating apoptosis and by 
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driving metabolic changes in BM-detached cells.16, 27, 33, 36, 37 Culture of MCF10A cells in 3D 
therefore constitutes a powerful tool for the study of oncogene-driven premalignant changes. 
The co-chaperone protein Bcl-2-associated athanogene 1 (Bag-1) is expressed at low levels 
in most human tissues43 but is frequently overexpressed in invasive breast carcinoma and 
importantly also within the preinvasive DCIS stage.4, 43-45, 47 In the clinical setting of breast 
cancer, Bag-1 mRNA is a prognostic biomarker included within the Oncotype DX and 
PAM50 multigene assays30, 31 and high nuclear Bag-1 immunoreactivity is an independent 
predictor of outcome and enhances the predictive power of IHC4 score (a combination of the 
prognostic information from ER, PgR, Ki67 and HER2 immunohistochemical staining).1, 6, 26, 
28, 47 At the cellular level, Bag-1 interacts with a number of protein partners including Bcl-2, 
Hsc70/Hsp70 chaperones and nuclear hormone receptors to promote cell survival.46 Proof-
of-principle studies from our laboratory have shown that it is possible to restrict breast 
cancer and melanoma cell growth by targeting Bag-1 protein-protein interactions using 
synthetic peptides and small-molecule compounds, like Thioflavin S and its biologically 
active constituent Thio-2.11, 39, 40 Bag-1 exists as three main isoforms Bag-1S and Bag-1M, 
which are mainly localised in the cytoplasm, and Bag-1L, which contains a nuclear 
localisation signal not present in the other isoforms and is predominantly localised in the 
nucleus.4, 22, 29, 38, 43, 48 Bag-1L, but not Bag-1M or Bag-1S, enhances the transcriptional 
activity of androgen receptor,14, 22, 41 vitamin D receptor24 and oestrogen receptor.6 Xenograft 
studies show that Bag-1L overexpression drives growth of breast tumours formed by 
oestrogen-responsive ZR-75-1 breast cancer cells in an oestrogen-dependent manner.23 
Although clinical studies and mouse models have shed some light on the role of Bag-1L in 
breast cancer pathology, little is known about the role of Bag-1L in initiating premalignant 
change in the breast. 
Studies using a 3D cell culture model have shown that concomitant co-overexpression of the 
main Bag-1 isoforms (Bag-1S, Bag-1M and Bag-1L) in MCF-10A cells leads to the formation 
of lumenless acini, through attenuation of anoikis in BM-detached cells, but without the 
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grape like abnormalities in morphology seen with HER2 overexpression. However, there is 
currently no evidence on the ability of individual Bag-1 isoforms to regulate acinar 
morphology.2 Based on published data supporting an important role of nuclear Bag-1L in 
breast cancer, in this study we sought to examine the effect of the individual Bag-1L isoform 
on acinar morphogenesis in order to elucidate and describe its role in promoting 
premalignant change in 3D. We then examined the effect of a small molecule inhibitor of 
Bag-1, Thio-2, in Bag-1L driven premalignant change in this experimental model of DCIS to 





Characterisation of Bag-1L overexpression in 2D culture 
To examine the potential role of Bag-1L in breast tumourigenesis, MCF-10A stable cell 
clones were generated by transfection of a pcDNA3 vector containing Bag-1 cDNA with an 
optimised Bag-1L start site.6 Immunoblot analysis revealed the presence of two clones 
overexpressing Bag-1L at low (Bag-1L/A) and high (Bag-1L/B) levels compared to two 
pcDNA-containing clones of which clone 1, designated pcDNA, was used as a control for 
this study (Figure 1a). Immunofluorescence staining revealed higher but heterogeneous 
expression of Bag-1 in the nucleus of both clones compared to pcDNA and was more 
intense in Bag-1L/B (Figure 1b), which is consistent with overexpression of Bag-1L.  
To characterise the effect of Bag-1L overexpression in 2D culture, cell morphology, colony 
forming efficiency, and proliferation were examined. Cell clones assumed a cobblestone 
appearance typically observed in parental MCF-10A cells with lamellipodia extending from 
the edges of clusters9 (Figure 1c). Bag-1L overexpression did not alter the colony forming 
efficiency of MCF-10A cells (Figure 1d) and supported neither anchorage-independent 
growth in vitro nor tumour growth in vivo (data not shown). Moreover, Bag-1L/B cells 
displayed a significant decrease in proliferation compared to pcDNA, as shown by a 38% 
reduction in crystal violet absorbance, whereas Bag-1L/A cells proliferated comparably to 
pcDNA controls (Figure 1e). 
 
Effect of Bag-1L overexpression on acini morphogenesis 
MCF-10A acini provide a physiologically relevant model to study the influence of Bag-1L 
overexpression on 3D morphology. Compared to pcDNA acini, Bag-1L protein level was 9-
fold higher in Bag-1L/A and 16-fold higher in Bag-1L/B, thereby providing a basis for the 
study of Bag-1L in acini morphogenesis (Figure 2a). Confocal microscopy images at day 20 
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of culture indicated formation of a central lumen in MCF-10A parental and pcDNA acini as 
expected (Figure 2b). In contrast, 26% of Bag-1L/A and 86% of Bag-1L/B acini were 
lumenless and significantly more abundant than the basal 9% lumenless acini formed by 
pcDNA cells (Figure 2b, c). Moreover, phase-contrast microscopical examination revealed 
that 16% of Bag-1L/A and 86% of Bag-1L/B acini assumed a branched morphology (Figure 
2d, e), which resembled an atypical phenotype in breast cancer cells reported by Kenny et 
al..21 Quantification of confocal and phase-contrast data indicated that the increase in Bag-
1L expression observed between Bag-1L/A and Bag-1L/B clones is associated with a 
significant 3.3-fold increase in the number of atypical acini formed with no central lumen 
(Figure 2c) and with altered external morphology (Figure 2e).  
To further characterise the effect of Bag-1L overexpression on acinar phenotype, cell 
proliferation and apoptosis were examined by immunofluorescence staining (Figure 3). At 
day 6 of culture, Ki-67, a protein marker of proliferation,15 was present in BM-attached cells 
situated at the periphery of control and Bag-1L/A-overexpressing acini, while in Bag-1L/B-
overexpressing acini it was present throughout (Figure 3a). At day 20 of culture, cells in 
control and Bag-1L-overexpressing acini exhibited minimal Ki67 staining consistent with the 
induction of growth arrest (Figure 3a). In addition, luminal apoptosis which was detected by 
M30 (antibody recognising caspase-cleaved cytokeratin 18) was markedly increased in 
parental and pcDNA acini but was almost undetectable in Bag-1L/A and Bag-1L/B acini 
(Figure 3b) at day 10 of culture. Taken together, these data show that overexpression of the 
Bag-1L isoform promotes an atypical acinar phenotype, as it impedes formation of a central 





Effect of HER2 overexpression on acini morphogenesis and comparison of 2D growth 
response to growth factors between Bag-1L- and HER2-overexpressing MCF-10A cells 
We next compared the 3D phenotypic changes observed in response to Bag-1L 
overexpression to a described and recognised27, 33 3D model of HER2 transformation that we 
generated. HER2 protein overexpression was confirmed by immunoblotting (Figure 4a) and 
immunofluorescence staining (Figure 4b). Lumen formation in acini grown to day 12 and 
stained with phalloidin was examined by confocal microscopy (Figure 4c, d) and external 
morphology quantified from high-resolution phase-contrast microscopy images (Figure 4e). 
As expected, parental and control puro cells gave rise to similar numbers of acini with a 
central lumen and a typical spherical structure (Figure 4c-e). In contrast, HER2 
overexpression resulted in a 4-fold increase in acini lacking a central lumen (Figure 4d) and 
a 3-fold increase in acini exhibiting branched morphology (Figure 4e) compared to puro 
control, in line with previous studies.27, 33 This 3D morphology was similar to that of Bag-1L-
overexpressing clones.  
Growth of MCF-10A cells requires insulin-like growth factor 1 (IGF-1),34 which is chemically 
and functionally similar to insulin and facilitates cellular glucose uptake.35 Overexpression of 
HER2 causes metabolic transformation of MCF-10A cells, which is characterised by insulin-
independent proliferation and enhances glucose uptake in the absence of IGF-1 receptor 
activity.3, 20, 37 Based on the phenotypic similarities between HER2- and Bag-1L-
overexpressing MCF10A cells in 3D, we investigated whether the atypical phenotype of Bag-
1L-overexpressing MCF-10A clones could also be due to metabolic changes associated with 
loss of responsiveness to insulin. To this end, cells were cultured in insulin-free or insulin-
containing media using HER2-overexpressing MCF-10A clones as a control. In line with 
previous studies,3 no significant difference in the growth of HER2-overexpressing clones 
was observed under these conditions (Figure 4f). Conversely, growth of puro and pcDNA 
controls, displayed a significant increase of ~1.4-fold in the presence compared to the 
absence of insulin (Figure 4f). Similarly, a growth increase of ~1.6-fold in Bag-1L/A and ~1.5-
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fold in Bag-1L/B was observed in the presence compared to the absence of insulin indicating 
responsiveness to this hormone. Moreover, all cell lines were responsive to EGF for growth 
(Figure 4f), consistently with previous reports.20 These data suggest that the mechanism 
responsible for the morphological changes observed in response to Bag-1L overexpression 
is likely to be different to that of HER2 and requires further investigation.  
 
Effect of Bag-1 inhibitors on 2D culture and acini morphogenesis 
To confirm the functional consequences of Bag-1L overexpression on 2D growth, MCF-10A 
clones were examined in the presence of Thioflavin S and Thio-2 inhibitors of Bag-1 protein-
protein interactions.12, 39 Viability assay data show that Thio-2 significantly decreased growth 
across all cell lines at 50 µM and 100 µM, while Thioflavin S had no effect (Figure 5a), 
confirming our previously published findings.12 Therefore, Thio-2 was used in subsequent 
experiments.  
We examined whether the atypical morphology of Bag-1L-overexpressing acini could be 
pharmacologically reversed. MCF-10A cells grown in 2D were pre-treated with Thio-2 for 24 
h before seeding on Matrigel with additional treatments administered on days 4 and 8 of 3D 
culture. Thio-2 treatment significantly reduced the number of atypical acini by 17% in Bag-
1L/A and 29% in Bag-1L/B compared to DMSO control (Figure 5b). Acini displaying atypical 
external morphology exhibited a reduced level of branching (Figure 5c) suggesting that 
changes in morphology could be due to Bag-1 protein-protein interactions. Furthermore, 
upon serum stimulation of serum-deprived cells there was no noticeable inhibitory effect by 
Thio-2 treatment on the activities of ERK and AKT as shown by immunoblot analysis (Figure 
5d). This could explain the lack of luminal clearing observed in Bag-1 overexpressing acini 
and is consistent with findings by Anderson et al.2 who showed that ERK activity needs to be 




Our data demonstrate, for the first time, that overexpression of the Bag-1L isoform alone is 
sufficient to suppress luminal apoptosis and drives the formation of MCF-10A acini with a 
branched morphology, which resemble transformed acini formed by HER2-overexpressing 
MCF-10A cells generated here by us, and published by others.27, 33 Although studies by 
Anderson et al. 2 revealed the existence of reduced luminal clearing in acini co-
overexpressing all three main Bag-1 isoforms (Bag-1S, Bag-1M, Bag-1L) no observation of 
abnormal branced morphology was reported. Similar to previous observations in non-
tumourigenic HaCaT skin epidermal keratinocytes,19 our data also show that Bag-1L 
overexpression results in decreased MCF-10A cell growth in 2D cultures, an event which 
seems to be inversely correlated to its level of expression. 
MCF-10A acini morphogenesis proceeds through a highly regulated sequence of events. 
Cell detachment from the BM in the lumen of acini induces cellular stresses resulting in 
anoikis and luminal clearing. This occurs through downregulation of ERK activity, resulting in 
potentiation of the pro-apoptotic activity of BimEL.
8-10, 36 Studies by Anderson et al.2 in which 
Bag-1S, Bag-1M, and Bag-1L isoforms were co-expressed in MCF-10A cells reveal that this 
process can be impeded by targeting the pro-apoptotic protein BimEL for proteasomal 
degradation through enhanced activation of the RAF-1/MEK/ERK signalling cascade. 
Although Thio-2 is known to downregulate the activity of ERK,12 and could partially reverse 
the branched acini morphology driven by Bag-1L overexpression, it did not induce anoikis of 
luminal cells. Studies by Debnath et al.8 have shown that apoptosis inhibition alone is 
insufficient to prevent luminal clearing, with Bcl-2 overexpression delaying but not completely 
preventing anoikis; this has implicated the existence of an additional metabolic mechanism 
involving the upregulation of cellular anti-oxidant defences.7, 37 To investigate the possibility 
that Bag-1L overexpression may suppress the metabolic impairments associated with 
detachment from the BM we examined insulin-stimulated growth based on the phenotypic 
resemblance observed between Bag-1L- and HER2-overexpressing acini. Although HER2 
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upregulation enhances glucose uptake independently of IGF-1 or insulin, leading to insulin 
insensitivity,3 Bag-1L-overexpression retained insulin responsiveness, indicating an inability 
for glucose uptake independently of insulin. This suggests that despite the phenotypic 
similarities, Bag-1L-overexpressing acini can overcome the metabolic defects associated 
with detachment via a different transforming mechanism to HER2.  
Targeting Bag-1 with its protein-protein interaction inhibitor Thio-2 attenuated the atypical 
branching of acini, suggesting that Bag-1L protein-protein interactions are important for 
determining the morphology displayed upon cell attachment to the BM. Importantly, the level 
of Bag-1L overexpression correlated with the phenotypic effect of compound treatment as 
Bag-1L/B clone exhibited the greatest reversal in morphology in response to treatment with 
Thio-2, thereby providing further evidence of a Bag-1L-driven phenotype. Although Anderson 
et al.2 described an inability of acini co-overexpressing Bag-1S, Bag-1M and Bag-1L to form 
a lumen, they did not report formation of a branched external morphology. This could be 
attributed to the regulatory balance exerted by the combined activities of individual Bag-1 
isoforms on cell-to-cell contact. Evidence for this comes from studies by Hinnit et al.19 who 
measured single-cell movement from small colonies of HGF-stimulated HaCaT cells using 
scatter assays. They show that constitutive Bag-1L overexpression results in greater than 2-
fold cell-to-cell dissociation, whereas Bag-1S and Bag-1M retain their cell-to-cell contacts 
and exhibit no scattering. When considered together with findings by Hinnit et al. and 
Anderson et al., our data emphasise the importance of the combined activities of distinct 
Bag-1 isoforms on cellular function, and support a role for Bag-1L in the formation of a 
premalignant phenotype, that might potentially be amenable to therapeutic intervention. 
In summary, our data describe a role for the Bag-1L isoform as a driver of phenotypic 
changes associated with a premalignant state in the breast using a 3D model of DCIS. Such 
changes seen in 3D models highlight the efficacy of these models to test the effects of 
inhibitors of breast tumour initiation in 3D that may not be seen in 2D. The ability of Thio-2 to 
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reverse some of these changes highlights the potential of Bag-1L-overexpressing MCF-10A 
acini as a model to test the effect of inhibitors of breast tumour initiation. 
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Materials and Methods  
Cell culture and generation of stable clones 
MCF-10A cells were obtained from LGC Standards (Middlesex, UK) and were cultured and 
maintained as described by Debnath et al..9 To generate Bag-1L clones, pcDNA3-Bag-1L or 
empty pcDNA3 vector were transfected into MCF-10A cells using FuGene HD (Promega, UK) 
and stable integrants selected with Geneticin (100 μg/ml; Sigma, UK). Single clones were 
harvested by trypsinisation using cloning rings and expanded. HER2 clones were generated 
as described by Debnath et al..9 Briefly, MCF-10A cells were infected using 0.45 µm filtered 
viral supernatant derived from Phoenix HEK-293 cells transfected with pBABEpuro-HER2 
vector18 (Addgene plasmid 40978), and were selected with puromycin (0.5 μg/ml). Resistant 
clones were pooled together by trypsinisation and expanded.  
 
Immunocytochemistry, image acquisition, and scoring of acini 
For 2D immunofluorescence staining, cells were plated on type I rat tail collagen-coated (10 
μg/ml) glass coverslips and processed as previously described.19 Acini were grown in 8 well 
culture slides (BD Falcon, UK) and were fixed in paraformaldehyde (2% v/v final conc.), 
which was added directly into culture media to minimise acini loss through aspiration; 
staining was performed as described by Debnath et al..9 Immunodetection was performed 
using antibodies raised against Ki67 (Abcam, UK), HER2 (CST, UK), keratin 18 Asp396 neo-
epitope (M30 CytoDEATHTM mAb, Enzo Life Sciences, UK), and Bag-1 (TB3 pAb, made in 
house 4); phalloidin-TRITC (Dako, UK) was used to stain the cytoskeleton and nuclei were 
stained with 4’6-diamidino-2-phenylindole (DAPI; Sigma, UK). Secondary antibodies were 
Alexa Fluor® 488 goat anti-mouse IgG and Alexa Fluor® 546 goat anti-rabbit IgG (Life 
technologies, UK). Imaging of 2D cultures was performed with an Olympus IX81 microscope. 
To quantify the external morphology of acini, mounted slides were viewed using an Olympus 
BX51 microscope with an automated slide scanning system (Olympus Soft Imaging Systems, 
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Munster, Germany) and high-resolution pictures covering the entire sample were captured 
using dotSlide v2.2 (Olympus Soft Imaging Solutions, GmbH). Images were viewed with 
Olympus OlyVIA v2.4 and morphology was scored by manual counting. To score acini 
luminal clearing or morphology, cross-sectional examination of all acini within each chamber 
was performed with a Leica SP5 confocal microscope; representative images were captured 
and analysed with LEICA LAS AF v2.6.0. 
 
Immunoblotting 
Lysates of 2D or 3D cultures were prepared in ice cold protease-supplemented (Sigma, UK) 
RIPA buffer (CST, UK). Acini extracts were dissociated through a 27-gauge needle and 
cleared by centrifugation (13,000 rpm, 15 min, 4°C). SDS-PAGE and immunoblotting were 
conducted according to standard protocols.17 Immunodetection was performed using 
antibodies raised against Bag-1 (3.10 G3E2, Santa Cruz Biotechnology, UK), HER2, 
p44/p42 MAPK (ERK1/2) (CST), phospho-p44/p42 MAPK (P-ERK1/2) (Thr202/Tyr204) 
(20G11) (CST), AKT (CST) and P-AKT Ser473 (CST). Anti-β-actin-HRP was from Sigma 
and secondary HRP-conjugated immunoglobulins were from Dako. Images were acquired 
with a BioRad Fluor-STM MultiImager using Quantity One analysis software v4.6.3. 
Quantification of bands was performed using the volume tools in Quantity One analysis 
software v4.6.6 (where a volume is the sum of the intensities of the pixels within the volume 
boundary, times by the pixel area). Analysis was carried out on bands pre-saturation. All 
bands were adjusted for global background volume. Protein abundance was calculated by 
normalising bands for actin, and expressed relative to pcDNA. 
 
Cell growth assays 
To measure growth, 20,000 cells/well were seeded in triplicate in 12 well plates and were 
fixed in ice cold methanol. Fixed cells were stained with 0.1% crystal violet and the 
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associated dye dissolved in 20% acetic acid to measure absorbance at 595 nm. For insulin 
and EGF responsiveness assays, cells which had been serum and growth factor starved for 
24 h were grown in the absence or presence of the relative growth factor for 48 h and were 
subsequently fixed in ice cold methanol and stained with 0.1% (w/v) crystal violet. The 
associated dye was extracted in 20% acetic acid and the absorbance at 595 nm was 
expressed relative to that of the growth factor-free condition.  
 
Bag-1 inhibition  
For dose-response experiments, 3,000 cells/well were seeded in triplicate in 96-well plates 
and were treated with DMSO, Thioflavin S (Sigma, UK) or Thio-2 (ref. 12) for 5 days. Cell 
viability was determined by CellTitre 96 Aqueous One solution assay (Promega) according 
to the manufacturer’s protocol. For acini morphogenesis assays, cells were pre-treated with 
compounds in 2D 24 h before seeding in compound-free assay media in 3D. Acini were fed 
with compound-containing assay media on days 4 and 8 of culture. To examine the effect of 
Thio-2 on signalling cell monolayers were rinsed with PBS and kept for 4 h in insulin and 
EGF free media containing reduced horse serum (0.5%). Cells were subsequently treated 
with compounds for 1 h and lysates were prepared after 10 min of horse serum (10%) 
stimulation. Unstimulated cells were used as negative controls for protein activation, while 
the MEK inhibitor U0126 (Promega) was used as a positive control for inhibition of ERK 
activity. 
 
Statistical analysis  
Statistical analysis was performed using GraphPad Prism version 6.00 (GraphPad Software, 
San Diego, USA) for Windows. Analyses of more than two groups were done using 2-way 
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Figure 1. Effect of Bag-1L overexpression on MCF-10A 2D cultures 
Bag-1 protein expression was examined in MCF-10A clones grown in 2D cultures as 
indicated by: (a) Immunoblot where β-actin was included as a control for loading and (b) 
immunocytochemical labelling for Bag-1 (red) and nuclear counterstain DAPI (blue); two 
exposure times are shown for Bag-1 staining; scale bars = 50 μm. (c) Phase-contrast 
images reveal that Bag-1L-overexpressing clones acquire a cobblestone morphology which 
is typical of MCF-10A cells. Scale bars = 200 μm. (d) The colony-forming efficiency of Bag-
1L clones was assessed in a clonogenic assay and expressed as the plating efficiency. 
Values represent the mean ± SEM from three independent experiments with triplicate 
determinations. (e) Proliferation of clones was measured at days 2 and 4 of culture. Cells 
(20,000 per well) were plated at day 0 and were fixed and stained with crystal violet. Stain 
was dissolved in 20% acetic acid and absorbance at 595 nm recorded. Bar graphs represent 
the mean ± SEM values from three independent experiments with triplicate determinations. * 
p ≤ 0.05, ** p ≤ 0.01 as determined by 2-way ANOVA with Bonferroni’s multiple comparisons.  
 
Figure 2. Bag-1L overexpression attenuates luminal clearing and promotes an 
abnormal acinar morphology 
(a) Immunoblot analysis showing expression of Bag-1 isoforms in lysates from MCF-10A 
acini clones cultured for 12 days; β-actin was included as a loading control. Densitometric 
analysis shows the abundance of Bag-1S and Bag-1L protein isoforms relative to pcDNA 
control. (b) Representative confocal immunofluorescence images taken through the centre 
of MCF-10A acini at day 20 of culture. Cells were stained with phalloidin-TRITC (green) and 
nuclei counterstained with DAPI (red); scale bars = 100 μm. (c) Acini with filled lumens were 
counted at day 20 of growth and their number is expressed as a percentage of total acini. (d) 
Representative phase-contrast images of MCF-10A cell clones grown in 3D for 20 days 
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revealing gross external morphology. White scale bars = 500 μm; black scale bars = 200 μm. 
(e) Acini with abnormal morphology were counted at day 20 of growth and their number is 
expressed as a percentage of total acini. Values represent the mean ± SEM from at least 
three independent experiments with duplicate determinations. * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 
0.0001 as determined by 2-way ANOVA with Bonferroni’s multiple comparisons. 
 
Figure 3. Bag-1L overexpression does not prevent cell cycle arrest but attenuates 
luminal apoptosis during acini morphogenesis 
Representative confocal immunofluorescence images taken through the centre of MCF-10A 
acini at the indicated time points of 3D morphogenesis. (a) Proliferation was examined using 
Ki67 (green) as a marker. (b) Apoptosis was assessed using M30 (green) as a marker of 
caspase-cleaved cytokeratin 18. Nuclei were counterstained with DAPI (red); scale bars = 
50 μm. 
 
Figure 4. HER2 overexpression promotes atypical MCF-10A morphology in 3D and 
insulin unresponsiveness in 2D cultures 
(a) Immunoblot analysis of HER2 overexpression in retrovirally-transduced MCF-10A pooled 
clones grown in 2D culture. Actin was included as a control for loading. (b) 
Immunofluorescence staining for HER2 (red) in 2D cultures of MCF-10A parental or 
retrovirally transduced with pBabe-puro vector control or pBabe-puro/HER2; nuclei were 
counterstained with DAPI (blue), while secondary antibody alone was used to exclude non-
specific staining; scale bars = 50 μm. (c) Representative confocal immunofluorescence 
images of MCF-10A acini at day 12 of growth on Matrigel. Acini were stained with phalloidin-
TRITC (green) and nuclei counterstained with DAPI (red); scale bars = 50 μm. The number 
of acini with (d) filled lumens (day 12) or (e) abnormal morphology (day 20) was counted and 
is expressed as a percentage of the total number of acini. Values represent the mean ± SEM 
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from three independent experiments with quadruplicate determinations. ** p ≤ 0.01, **** p ≤ 
0.0001 as determined by 2-way ANOVA with Bonferroni’s multiple comparisons. (f) Insulin 
and EGF sensitivity was assessed in 2D culture under serum-free conditions (24 h serum 
starvation) following treatment for 48 h as indicated. Bar graphs represent the mean fold 
change ± SEM in cell growth in growth factor-supplemented relative to growth factor-free 
media for each cell line, which was determined by crystal violet assay. Data are from at least 
three independent experiments with triplicate determinations. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
0.001, **** p ≤ 0.0001 as determined by 2-way ANOVA with Bonferroni’s multiple 
comparisons. 
 
Figure 5. Thio-2 can partially reverse the abnormal acinar morphology associated with 
Bag-1L overexpression 
(a) MCF-10A cells were treated with Thioflavin S or Thio-2 at the indicated concentrations for 
5 days and viability was assessed by CellTiter Aqueous One solution assay relative to 
DMSO-treated cells at each concentration. Values represent the mean ± SD as percent of 
control from three experiments with triplicate determinations. **** p ≤ 0.0001 was determined 
by 2-way ANOVA with Bonferroni’s multiple comparisons relative to the effect of the lowest 
concentration of Thio-02 on each corresponding cell. (b) MCF-10A cells were treated for 24 
h with Thio-2 (50 μM) or DMSO (0.5% v/v) before seeding on Matrigel and acini were 
allowed to form over 14 days; further treatment (25 μM Thio-2 or 0.25% v/v DMSO) was 
administered on days 4 and 8 of 3D culture. Acini exhibiting abnormal morphology were 
quantified and expressed as a percentage of the total number. Values represent the mean ± 
SEM from four independent experiments with duplicate determinations. * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001 as determined by 2-way ANOVA with Bonferroni’s multiple comparisons. 
(c) Representative phase-contrast microscopy images show the atypical branching external 
morphology of Bag-1L/B is acini in the presence of DMSO or Thio-2. Scale bars = 50 μm. (d) 
Immunoblot analysis shows the effect of serum (10%) stimulation alone or in in the presence 
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of DMSO (0.5%), Thio-2 (50 µM), or U0126 (25 µM) on the activation of ERK and AKT in 
cells that had been serum-deprived. β-actin was used as a loading control. 





